Takeda Chemical Industries Ltd. said Thursday it has agreed with Andrx Corp. of the United States to jointly develop a drug for diabetes on the basis of their existing products for treating the disorder.

Under the agreement, the leading Japanese pharmaceutical company and the U.S. firm will join hands in developing a combination drug based on Takeda’s Actos and Andrx’s Fortamet, Takeda said in a news release.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.